Traffic Lights - Latest Updates

Last updated: 23/09/2021

Other updates on this site
Drug Name Classification Clinical Indication Comments
ACITRETIN (UPDATED) Red For psoriasis, Icthyosis, palmoplantar pustulosis and Dariers disease in males and postmenopausal women.

Reviewed by TAS 22nd June 2021

ALBUTREPENONACOG ALPHA (Idelvion®) (NEW) Red Prophylaxis and treatment of bleeding in Haemophilia B
ALPHA-TOCOPHEROL (VITAMIN E) (NEW) Red When given with pentoxifylline or the treatment of persistently thin endometrium during IVF therapy
AMIKACIN (Arikayce Liposomal®) (NEW) Black Non-tuberculous mycobacterial (NTM) lung infections

Not yet reviewed

ANAKINRA (Kineret®) (NEW) Red Still’s disease and juvenile idiopathic arthritis

In line with NICE TA685

Implementation date 30th June

ANDEXANET ALFA (Ondexxya®) (NEW) Red Reversing anticoagulation from apixaban or rivaroxaban in adults for life-threatening or uncontrolled GI bleed.

In line with NICE TA697

ANTITHROMBIN recombinant (UPDATED) Red Congenital antithrombin deficiency
ASCORBIC ACID PASCOE 150 MG/ML CONCENTRATE FOR SOLUTION FOR INJECTION / INFUSION (NEW) Black Treatment of clinical vitamin C deficiency

Not yet reviewed

AVATROMBOPAG (Doptelet®) (NEW) Black Severe thrombocytopenia

Not yet reviewed

AZATHIOPRINE (NEW) Amber Full SCA Autoimmune neurological disorders

Please see shared care agreement for individual indications

BARICITINIB (NEW) Red Moderate to severe atopic dermatitis

In line with NICE TA681

Implementation date 3rd June 2021

BElIMUMAB (UPDATED) Red Active autoantibody-positive systemic lupus erythematosus. Rheumatology only
BEMPEDOIC ACID (Nilemdo®) (UPDATED) Red Primary hypercholesterolaemia or mixed dyslipidaemia in adults

In line with NICE TA694

Implementation date 28th July 2021

BEMPEDOIC ACID / EZETIMIBE (Nustendi®) (UPDATED) Red Primary hypercholesterolaemia or mixed dyslipidaemia in adults

In line with NICE TA694

Implementation date 28th July 2021

BEROTRALSTAT (NEW) Red Prevention of recurrent attacks of hereditary angioedema (HEA)
BOTULINUM TOXIN B (Neurobloc®) (UPDATED) Red Neurology use only
BROLUCIZUMAB (Beovu®) (UPDATED) Red Wet ARMD

In line with NICE TA672

BUDESONIDE (1mg orodipersible tablet) (Jorveza®) (UPDATED) Red For treatment of eosinophilic esophagitis in adults and children

NICE TA708

BUPRENORPHINE PROLONGED RELEASE INJECTION (Buvidal®) Red Substance misuse

Used by Turning Point . If a patient is admitted to hospital contact turning point for advice about alternatives:

0116 3732117 – Direct dial to prescribing team

0116 3732108 – Direct Dial to Clinical Admin

0330 303 6000 – Main Switchboard

BUSPIRONE (NEW) Red Gastroparesis/functional dyspepsia
CAPLACIZUMAB (Cablivi®) (UPDATED) Red Acquired TTP

In line with NICE TA667 

Implementation date 16th March 2021

CEFIDEROCOL SULFATE TOSYLATE (Fetcroja®) Black Treatment of infections due to aerobic Gram-negative organisms

Not yet reviewed

CICLOSPORIN EYEDROPS (Verkazia®) (NEW) Amber Simple Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents
COLISTIN (NEW) Red Nebulised for Cystic fibrosis
COLISTIN (Colomycin® and Promixin ®) Amber Full SCA Nebulised for cystic fibrosis

Historic patients only. Must be prescribed by brand as the brands are not interchangeable.

DALBAVANCIN (Xydalba®) (NEW) Red Osteoarticular infections (unlicensed)
DAPAGLIFLOZIN (Forxiga®) (NEW) Amber Simple Chronic Heart failure with reduced ejection fraction

In line with NICE TA679

DEFLAZACORT (Calcort®) (NEW) Red Duchenne muscular dystrophy
DEXMEDETOMIDINE (Dexdor ®) (NEW) Red Pre procedure sedation in children
DULOXETINE (NEW) Green Anxiety and depression
EMTRICITABINE/TENOFOVIR DISOPROXIL (Ictastan®) (UPDATED) Red HIV
ERENUMAB 70mg injection (Aimovig®) (UPDATED) Red Migraine prophylaxis

In line with NICE TA682

Implementation date 10th June 2021

ESKETAMINE HYDROCHLORIDE NASAL SPRAY (Spravato®) (UPDATED) Red In combination with a SSRI or SNRI for adults with treatment-resistant Major Depressive Disorder

Administration in specialist clinic only

ESTRADIOL VAGINAL TABLETS (Vagirux®) (NEW) Green Vaginal atropy in post menopausal women
FILGOTINIB (Jyseleca®) (NEW) Red Moderate to severe arthritis

In line with NICE TA676

Implementation date 24th May 2021

FLUTICASONE/UMECLIDINIUM/VILANTEROL DRY POWDER INHALER (Trelegy Ellipta®) (NEW) Black COPD

Reviewed by the respiratory group

FORMOTEROL/BUDESONIDE/GLYCOPYRRONIUM INHALER (Trixeo Aerospace®) (NEW) Black Moderate to severe COPD

Not yet reviewed

GALCANEZUMAB (Emgality ®) (UPDATED) Red Migraine prophylaxis

In line with NICE TA659

GLYCEROL PHENYLBUTYRATE (Ravicti®) (UPDATED) Red Chronic management of patients with urea cycle disorders (UCDs)
GLYCOPYRRONIUM/FORMOTEROL INHALER (Bevespi aerosphere®) (NEW) Black COPD

Not yet reviewed

GUSELKUMAB (NEW) Red Treating active psoriatic arthritis after inadequate response to DMARDs

In line with NICE TA711

HUMAN FIBRINOGEN & HUMAN THROMBIN (Veraseal®) (NEW) Red Supportive treatment in adults where standard surgical techniques are insufficient; for improvement of haemostasis & as suture support in vascular surgery
HYDROXYCHLOROQUINE (UPDATED) Amber Simple Rheumatological disease

Eye checks to be organised by secondary care.

IMIPENEM/CILASTATIN/ RELEBACTAM (Recarbrio®) (UPDATED) Red Aerobic Gram-negative infections
INCLIRISAN (Leqivo®) (NEW) Black Primary hypercholesteraima and mixed dyslipidaemia

Not yet reviewed

INDACATEROL/MOMETASONE dry powder inhaler (Atectura Breezhaler®) (NEW) Black Maintenance treatment of asthma in adults and adolescents 12 years of age and older

Not yet reviewed

INHALED DRY POWDER BUDESONIDE (NEW) Green Covid 19 treatment commenced in primary care for patients 50 years and over.

In line with CAS alert 103154 

See CAS alert and alert attachments for more information including eligibility and duration of treatment and  also see the formulary

 

Klean-Prep® (UPDATED) Green Bowel cleansing before lower GI endoscopy (second line)

In line with prism pathway (currently under development, traffic light change in readiness)

LEUPRORELIN (PROSTAP 3 DCS ®) (NEW) Amber Simple Breast cancer

3 monthly preparation

LIDOCAINE Patch (UPDATED) Black All indications except post herpetic neuralgia

New patients initially. Further advice to come regarding historic patients

LIRAGLUTIDE (Saxenda®) (UPDATED) Red Obesity as part of a tier 3 specialist weight management service

In line with NICE TA664

LUSUTROMBOPAG (Mulpleo®) (NEW) Black Severe thrombocytopenia

Not yet reviewed

MBrIDA (NEW) Red Diagnosis of hepatobiliary tract patency and differentiation of jaundice
Moviprep® (UPDATED) Green Bowel cleansing before lower GI endoscopy (first line)

In line with prism pathway (currently under development, traffic light change in readiness)

MYCOPHENOLATE MOFETIL (NEW) Amber Full SCA Autoimmune conditions

Please see shared care agreement for individual indications

NONACOG BETA PEGOL (Refixia®) (UPDATED) Red Haemophilia
OFATUMUMAB (Kesimpta ®) (NEW) Red For treating relapsing multiple sclerosis

In line with NICE TA699

Implementation date 19th August 2021

ONASEMNOGENE ABEPARVOVEC (Zolgensma®) (NEW) Black 5q spinal muscular atrophy (SMA)

Not yet reviewed

OPIATE/MORPHINE TINCTURE (Dropizol® oral drops) (NEW) Black Severe diarrhoea

Reviewed by TAS 22nd June 2021

OPTIVE PLUS (UPDATED) Black Dry eye
OXANDROLONE (UPDATED) Red Prophylaxis of acute attacks in hereditary angioedema. Third line after danazol and stanozolol when stanozolol is unavailable
PENTOXIFYLLINE (Trental®) (NEW) Red When given with alpha tocopherol (vitamin E) for the treatment of persistently thin endometrium during IVF therapy
PERGOLIDE (UPDATED) Black Parkinson's disease

No longer recommended

PONESIMOD (Ponvory®) (NEW) Black Relapsing forms of multiple sclerosis with active disease.

Not yet reviewed

PRIDINOL (Myopridin®) (NEW) Black Central and peripheral muscle spasms, lumbar pain, torticollis and general muscle pain

Not yet reviewed

RAVULIZUMAB (NEW) Black Treating atypical haemolytic uremic syndrome (aHUS)

Only for use in specialist centres (which are not in LLR at present) as per NICE TA710.

RAVULIZUMAB (Ultomiris®) (UPDATED) Black Paroxysmal nocturnal haemoglobinuria

In line with NICE TA698 this product should be used by specialist centres only. At the time of classification LLR is not a site of a specialist centre.

REMIMAZOLAM (Byfavo®) (NEW) Black Procedural sedation in adults.

Not yet reviewed

Salmeterol and Fluticasone inhalation powder (Fixkoh Airmaster®) (NEW) Black Asthma and COPD

Not yet reviewed

SEMAGLUTIDE (Rybelsus®) (UPDATED) Green Type 2 diabetes
SIMPLE EYE OINTMENT (UPDATED) Black Dry eye
SIPONIMOD FUMARIC ACID (Mayzent®) (UPDATED) Red Secondary progressive multiple sclerosis in adults

In line with NICE TA656

SOLRIAMFETOL (Sunosi ®) (UPDATED) Red Excessive daytime sleepiness in narcolepsy
SOLRIAMFETOL (Sunosi ®) (UPDATED) Red Residual sleepiness in optimally CPAP treated obstructive sleep apnoea
SUGAMMADEX (Bridion®) (UPDATED) Red Reversal of neuromuscular blockage induced by rocuronium or vecuronium
TACROLIMUS (Advagraf®) (NEW) Red Continuation of hepatic transplant immunosuppression for patients transferred from out of area tertiary centre only
TRALOKINUMAB (Adtralza ®) (NEW) Black Treatment of moderate-to-severe atopic dermatitis in adult

Not yet reviewed

TRANSDERMAL ESTRADIOL SPRAY (Lenzetto®) (NEW) Green Symptoms of menopause
TRI-IODOTHYROACETIC ACID (TRIAC) (Emcitate®) (NEW) Black Allan-Herndon Dudley syndrome associated with MCT-8 deficiency

Reviewed by TAS 22nd June 2021

UPADACITINIB (RINVOQ®) (UPDATED) Red Rheumatoid arthritis

In line with NICE TA665

VERICIGUAT (Verquvo®) (NEW) Black Chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy.

Not yet reviewed

VIGABATRIN (UPDATED) Amber Simple Epilepsy

Clarification of historical status

ZOSTAVAX (Varicella zoster vaccine) (UPDATED) Black Prevention of shingles and post-herpetic neuralgia including immunisation of non-immune individuals prior to starting a course of immunosuppressant medication. Live vaccine, therefore NOT suitable for immunocompromised patients. Do not prescribe on FP10 (black through this route).

Available centrally from 1st Sept 2013 for those aged 70 and 79 years
Public Health advice

Other Updates on this Website

Recent documents from LMSG and TAS


About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more